Evidence-Based Medical News

Mode

All Oncology Infectious Disease Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Primary Care & Family Medicine Gastroenterology Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Anesthesiology & Pain Medicine Genetics & Precision Medicine Pulmonology & Critical Care Physical Medicine & Rehab Urology Nephrology Emergency Medicine Ophthalmology Hematology Dermatology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Fallopian tube cancer

Part of Adnexal Diseases

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Fallopian tube cancer

93 trials tracked for Fallopian tube cancer: 13 in phase 3 or 4 and 7 with published results. The most-cited published study has 505 citations.

93Trials tracked

13Phase 3 & 4

0Recruiting

7With published results

Phase distribution

Phase 3 13 Phase 2 65 Phase 1 11 Other / NA 4

Show 44 more trials

Phase 3 A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed · 20 cited
Phase 3 Accelerating Gastrointestinal Recovery Completed
Phase 3 CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib Completed
Phase 3 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) Completed
Phase 3 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed
Phase 3 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed
Phase 3 Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer Completed
Phase 2 Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer Completed
Phase 2 A Study LY2228820 for Recurrent Ovarian Cancer Completed
Phase 2 Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer Completed
Phase 2 Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed
Phase 2 A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) Completed
Phase 2 Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Completed
Phase 2 Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed
Phase 2 European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer Completed
Phase 2 Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer Completed
Phase 2 A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Completed
Phase 2 A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed
Phase 2 Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers Completed
Phase 2 Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Completed
Phase 2 Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed
Phase 2 Study of Ramucirumab in Ovarian Cancer Completed
Phase 2 AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed
Phase 2 Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Completed
Phase 2 S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed
Phase 2 Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer Completed
Phase 2 Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies Completed
Phase 2 Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer Completed
Phase 2 A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers Completed
Phase 2 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed
Phase 2 Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer Completed
Phase 2 A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) Completed
Phase 2 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed
Phase 2 Irinotecan and Bevacizumab for Recurrent Ovarian Cancer Completed
Phase 2 Neoadjuvant Therapy for Ovarian Cancer Completed
Phase 2 Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed
Phase 2 Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab Completed
Phase 2 Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer Completed
Phase 2 Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers Completed
Phase 2 A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment Completed
Phase 2 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed
Phase 2 Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer Completed
Phase 2 Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer Completed
Phase 2 Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer Completed

Showing the 50 most-cited and recently-updated of 93 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Fallopian tube cancer: what the trials found

New clinical evidence highlights the efficacy of several targeted and systemic therapies. Pembrolizumab demonstrated a 95% progression-free survival (PFS) rate at 6 months when following pre-trial weekly Paclitaxel ¹, while also showing significant improvement in PFS for patients with PD-L1 positive tumors compared to other cohorts ¹². Rucaparib showed superior investigator-assessed progression-free survival (invPFS) and duration of response (DOR) compared to chemotherapy [9, 10].

Mirvetuximab soravtansine demonstrated significant clinical activity across multiple trials. It achieved high CA-125 confirmed clinical response rates in various cohorts [2, 6, 7, 8] and showed statistically significant improvements in progression-free survival compared to other regimens ⁶. Additionally, Mirvetuximab soravtansine was associated with varying objective response rates (ORR) across different dose expansion and escalation protocols ²⁰.

Paclitaxel remains a standard of care; however, results varied across studies. One trial showed no significant difference in 6-month PFS or overall survival between Paclitaxel arms ¹⁵, while another demonstrated significantly improved progression-free survival in one specific cohort compared to others ¹¹.

Recent results — preliminary, needs further review

Pegylated Liposomal Doxorubicin + SL-172154 is currently under investigation in a Phase 1 trial ³.

For the clinician treating this condition

Rucaparib has demonstrated superior progression-free survival and duration of response compared to chemotherapy [9, 10].
Mirvetuximab soravtansine shows consistent clinical activity with significant improvements in progression-free survival and high CA-125 response rates across multiple studies [6, 7, 8].
Pembrolizumab showed a 95% 6-month PFS rate following pre-trial Paclitaxel and demonstrated efficacy in PD-L1 positive populations [1, 12].

AI synthesis of 7 cited trials, updated Jun 21, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.